Department of Hematology, University of Crete School of Medicine, Heraklion, Crete, Greece.
Expert Rev Hematol. 2011 Jun;4(3):317-28. doi: 10.1586/ehm.11.26.
Large granular lymphocyte (LGL) syndrome includes a spectrum of clonal T cell and natural killer cell chronic lymphoproliferative disorders. These conditions are thought to arise from chronic antigenic stimulation, while the long-term survival of the abnormal LGLs appears to be sustained by resistance to apoptosis and/or impaired survival signaling. T-cell LGL (T-LGL) leukemia is the most common LGL disorder in the Western world. Despite its indolent course, the disease is often associated with neutropenia, the pathogenesis of which is multifactorial, comprising both humoral and cytotoxic mechanisms. This article addresses the pathogenesis of T-LGL leukemia and natural killer cell chronic lymphoproliferative disorder, as well as that of T-LGL leukemia-associated neutropenia. Furthermore, as symptomatic neutropenia represents an indication for initiating treatment, available therapeutic options are also discussed.
大颗粒淋巴细胞(LGL)综合征包括一系列克隆性 T 细胞和自然杀伤细胞慢性淋巴增殖性疾病。这些疾病被认为是由慢性抗原刺激引起的,而异常 LGL 的长期存活似乎是通过抵抗细胞凋亡和/或受损的存活信号来维持的。T 细胞 LGL(T-LGL)白血病是西方世界最常见的 LGL 疾病。尽管其病程惰性,但该疾病常伴有中性粒细胞减少症,其发病机制是多因素的,包括体液和细胞毒性机制。本文讨论了 T-LGL 白血病和自然杀伤细胞慢性淋巴增殖性疾病的发病机制,以及 T-LGL 白血病相关中性粒细胞减少症的发病机制。此外,由于症状性中性粒细胞减少症是开始治疗的指征,因此还讨论了可用的治疗选择。